ZyVersa Therapeutics Bolsa (NASDAQ: ZVSA)

Últimas noticias sobre ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

Earnings

News

Southeast Airport Group Q3 2024 GAAP EPS $5.7374 Beats $5.73 Estimate

This closure is part of the Company&rsquo;s Fit to Win initiative to reduce redundant capacity and begin to optimize its network. Additional furnace closures and other restructuring actions are expected later in 2024.
The furnace closure is expected to occur on or after November&nbsp;18, 2024. The Company intends to facilitate the closure in a respectful manner for the approximately 150 people impacted.&nbsp;&nbsp;
Subject to finalization of certain estimates, the Company expects to record a charge associated with this closure of approximately $39 million in the third quarter of 2024.&nbsp; Major components of the charge include approximately $24 million for impairment of plant-related assets, such as the closed furnace and related machinery, and $15 million for one-time employee separation benefits and other costs related to the closing (of which approximately $10 million relate to future cash expenditures).

On October 21, O-I Glass Finalizes Plans For Closure Of A Furnace In Its Americas Segment

WIIM

Seagate Technology shares are trading lower. The company reported Q1 financial results.

Buybacks

SEIC

SEI Expands Stock Repurchase Program By $400M, Bringing Total Authorization To Approximately $429M

CSGP

CoStar shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Packaging Corp shares are trading higher after the company reported better-than-expected Q3 financial results.

Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.82 by 2.44 percent. The company reported quarterly sales of $195.581 million which beat the analyst consensus estimate of $192.457 million by 1.62 percent. This is a 0.73 percent increase over sales of $194.160 million the same period last year.

Earnings Beats

TRMK

Trustmark Q3 2024 Adj. EPS $0.84 Beats $0.82 Estimate, Sales $195.581M Beat $192.457M Estimate

Franklin Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRAF#NASDAQ">FRAF</a>) reported quarterly earnings of $0.95 per share. This is a 7.95 percent increase over earnings of $0.88 per share from the same period last year.

FRAF

Franklin Financial Servs Q3 EPS $0.95 Up From $0.88 YoY

Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported its third-quarter financial results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/n41465683/ti-reports-third-quarter-2024-financial-results-and-shareholder-returns">details from the report.&nbsp;</a>
The Details: Texas Instruments reported quarterly earnings of $1.47 per share, which beat the analyst consensus estimate of $1.37. Quarterly revenue of $4.151 billion beat the consensus estimate of $4.12 billion.
&#8220;Industrial continued to decline sequentially, while all other end markets grew. Our cash flow from operations of $6.2 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300mm production. Free cash flow for the same period was $1.5 billion,&#8221; said Haviv Ilan, CEO of Texas Instruments.
&#8220;Over the past 12 months we invested $3.7 billion in R&amp;D and SG&amp;A, invested $4.8 billion in capital expenditures and returned $5.2 billion to owners,&#8221; Ilan added.
Read Next: <a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a>
Outlook: Texas Instruments sees fourth-quarter earnings between $1.07 and $1.29 per share, versus the $1.34 estimate and quarterly revenue in a range of $3.7 billion to $4 billion, versus the $4.07 billion consensus estimate. 
TXN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Texas Instruments shares are seesawing after the close, but at publication on Tuesday were up 0.015% at $194.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a></li>
</ul>
Photo: Shutterstock&nbsp;

After-Hours Center

Movers

Tech

Texas Instruments Shares Seesaw After Q3 Results Beat Estimates, Weak Q4 Guidance

The First Bancshares, Inc. ("The First") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBMS#NYSE">FBMS</a>), holding company for The First Bank, (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.thefirstbank.com&amp;esheet=54140569&amp;newsitemid=20241022552905&amp;lan=en-US&amp;anchor=www.thefirstbank.com&amp;index=1&amp;md5=48fd2241736b076ad99d73a53a69831d">www.thefirstbank.com</a>), announced today that the previously announced merger between The First and Renasant Corporation ("Renasant"), pursuant to the Agreement and Plan of Merger, dated as of July 29, 2024, (the "Merger Agreement"), has been approved by its shareholders. Completion of the transaction remains subject to customary closing conditions, including the receipt of required regulatory approvals.

FBMS

The First Bancshares Announces Receipt Of Shareholder Approval For Merger

BROS

Dutch Bros shares are trading lower amid sympathy with Starbucks after the company reported Q4 financial results and suspended 2025 guidance.

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 18.31% on an annualized basis producing an average annual return of 29.7%. Currently, Tesla has a market capitalization of $696.36 billion. 
Buying $100 In TSLA: If an investor had bought $100 of TSLA stock 10 years ago, it would be worth $1,474.96 today based on a price of $217.98 for TSLA at the time of writing.
<h3>Tesla's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629259_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TSLA

$100 Invested In Tesla 10 Years Ago Would Be Worth This Much Today

Kroger will use RFID sensors to enable item-level digital identification for greater inventory accuracy to maximize freshness, reduce waste and optimize associates' time
Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) announced today it will begin working with The Kroger Co. to build a better associate and customer experience through RFID inventory automation technology. This collaboration makes item-level digital identification possible, enabling more frequent and more accurate inventory information to maximize freshness, reduce waste and improve the associate experience.

Avery Dennison Announces It Will Begin Working With The Kroger Co. To Build A Better Associate And Customer Experience Through RFID Inventory Automation Technology

MANH

Manhattan Associates shares are trading lower. The company reported Q3 financial results.

WFRD

Weatherford Q3 Revenue $1.409B; GAAP EPS $2.06 Per Share Vs $1.66 In Q2

PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) reported quarterly earnings of $3.49 per share which beat the analyst consensus estimate of $2.90 by 20.34 percent.

Earnings Misses

PFSI

PennyMac Financial Servs Q3 2024 Adj EPS $3.49 Beats $2.90 Estimate

Bank of N.T Butterfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTB#NYSE">NTB</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $142.700 million which beat the analyst consensus estimate of $142.472 million by 0.16 percent. This is a 0.71 percent increase over sales of $141.700 million the same period last year.

Bank of N.T Butterfield Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $142.700M Beat $142.472M Estimate

Biotech

General

ANRO

Alto Neuroscience Announces That The Phase 2b Study Of ALTO-100 In Patients With Major Depressive Disorder Did Not Meet Its Primary Endpoint, Assessed By A Change From Baseline In Montgomery-Åsberg Depression Rating Scale, Compared To Placebo

Argentina has introduced new regulations for the hemp industry through&nbsp;Resolution 1/2024, signed by Ignacio Ferrari, director of the Regulatory Agency for the Hemp and Medicinal Cannabis Industry (ARICCAME). 
These regulations introduce a simplified system that distinguishes between agricultural and industrial activities.
ARICCAME, which oversees hemp and cannabis activities, <a href="https://www.benzinga.com/markets/cannabis/24/09/40926566/argentinas-cannabis-industry-shakeup-will-the-new-government-appointed-comptroller-boost-busines">has been restructured</a> under to resolve operational issues.
The agency&#8217;s new leadership now holds expanded powers to issue licenses and coordinate with other regulatory authorities to ensure compliance with the updated regulations, first <a href="https://elplanteo.com/regulaciones-canamo-licencias-argentina/">reported</a> El Planteo.
<h3 class="wp-block-heading">Argentina's Hemp Potential In the Global Market</h3>
Argentina is already a key player in global agriculture, known for its vast production of commodities like soybeans, meat and corn.
The country's agricultural prowess positions it as a potential major exporter of hemp, offering products like seeds, fibers and oils at competitive prices.
If Argentina's <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/markets/cannabis/24/08/40418137/industrial-hemps-14b-projected-growth-an-investment-opportunity-too-good-to-miss&amp;ved=2ahUKEwiMotKLpaKJAxUuqpUCHabjC6cQFnoECBMQAQ&amp;usg=AOvVaw0tIRFytMtpZRpfLvkTSE66">hemp industry</a> gains momentum, it could drive down global prices and create significant opportunities in international markets, benefiting industries like textiles and pharmaceuticals.
This development could also provide competition to <a href="https://www.benzinga.com/markets/cannabis/24/09/40715126/expert-economist-slashes-hemp-acreage-forecast-by-82-for-2030-heres-why">U.S. hemp producers</a>, as Argentina&#8217;s scale and efficiency may help meet growing global demand at a lower cost.
<ul>
<li>Learn all about Argentina's booming cannabis industry and opportunities ahead at El Planteo's <a href="https://elplanteo.com/eventos/cannab2b/" target="_blank" rel="noreferrer noopener">CannaB2B</a> event in Buenos Aires on November 4. <a href="https://share.hsforms.com/1dzCltrUDRSGMSOTerkComg1npzh?__hstc=99187265.ce2611b4134345745d71884123d3462e.1707500707807.1726678078078.1726684863653.678&amp;__hssc=99187265.1.1726684863653&amp;__hsfp=22530479" target="_blank" rel="noreferrer noopener">Sponsorship opportunities</a> are now open.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40926566/argentinas-cannabis-industry-shakeup-will-the-new-government-appointed-comptroller-boost-busines">Argentina&#8217;s Cannabis Industry Shakeup: Will The New Government-Appointed Comptroller Boost Business Opportunities?</a>
<h3 class="wp-block-heading">Key Licensing Changes And Fees</h3>
One of the significant updates is the repeal of&nbsp;Resolution No. 2/2023, which governed provisional permits for activities involving cannabis. Existing permits will remain valid until their expiration, but new applications must follow the updated framework.
The new resolution outlines two types of licenses for <a href="https://www.benzinga.com/topic/hemp">industrial hemp</a> production:
<ul>
<li>Agricultural License: Covers cultivation, transportation, and processing of hemp seeds and fiber.
<ul>
<li>0-100 hectares: no cost.</li>
<li>101-500 hectares: $500,000 annually ($550)</li>
<li>501-1000 hectares: $1,000,000 annually ($1100)</li>
<li>More than 1000 hectares: $2,000,000 annually. ($2200)</li>
</ul>
</li>
<li>Industrial License: Governs commercialization, distribution, import, and export of hemp products, with an annual fee of $1,000,000. ($1100)</li>
</ul>
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41371814/guaran-cannabis-lands-in-europe-paraguay-to-export-100-of-its-flower-production">Guaraní Cannabis Lands In Europe: Paraguay To Export 100% Of Its Flower Production</a>
Cover: Benzinga edit based on&nbsp;Photo by <a href="https://unsplash.com/es/@eirhealth?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Eir Health</a>&nbsp;via Unsplash <a href="https://unsplash.com/es/fotos/un-gran-grupo-de-plantas-verdes-en-un-campo-KPoxs_DA500?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Cannabis

Markets

Hemp Finally Gets Regulated In Argentina: Will It Boom Like The Country's Many Other Ag Products?

TGLS

Tecnoglass shares are trading lower. Sidoti & Co. downgraded the stock from Buy to Neutral and announced a price target of $78.

PHG, IBRX and MESO are among premarket gainers

ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers

CRVS, CTMX and NRXP are among premarket  gainers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) just reported results for the first quarter of 2024.<ul><li>ZyVersa Therapeutics reported earnings per share of -$4.53. This was below the analyst estimate for EPS of -$3.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/zvsa-stock-earnings-zyversa-therapeutics-for-q1-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024

ZyVersa Therapeutics GAAP EPS of -$4.53 misses by $0.78

ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) just reported results for the second quarter of 2024.<ul><li>ZyVersa Therapeutics reported earnings per share of -$3.31. This was above the analyst estimate for EPS of -$3.75.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/zvsa-stock-earnings-zyversa-therapeutics-for-q2-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024

ZyVersa Therapeutics files for mixed shelf offering

Warning: ZVSA is at high risk of performing badly

ABVC

ADXN

AGBA

AQST

ATXI

BENF

CJJD

CLVR

DCPH

HOLO

HSAI

IBRX

ICLK

IMTE

INCR

MESO

NITO

NIVF

NUVO

OPTN

SLNO

SWIN

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Press Releases

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

Health Care

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Analyst Ratings

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Comments

ZyVersa Therapeutics

Noticias

Últimas noticias sobre ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL